Craig England, the founding partner of England & Company, is an investment banker with over 30 years of experience in M&A advisory, financial restructuring services, and private finance.
Prior to forming England & Company, Mr. England was a Principal in Legg Mason’s Investment Banking Group where he concentrated on software and financial services companies. Prior to Legg Mason, he was a Vice President with Alex. Brown & Sons in New York and Baltimore where he led the firm’s Asset Securitization Group. Additionally, Mr. England served as a Vice President and private placement specialist at New York City-based Hunter, Keith, Marshall & Co., and Corporate Finance Director for ICON Capital Corp. He began his career as a corporate lender in the financial institutions groups of the Irving Trust Company (now the Bank of New York) and the Canadian Imperial Bank of Commerce.
Mr. England earned his BA from the Johns Hopkins University, completed studies in International Economics at the Universite Libre de Bruxelles and received his MBA in Finance from the Stern School of Business at New York University.
Andy Cowherd has over 25 years of investment banking and private equity investing experience focused on the healthcare sector. In these roles, he has completed a wide range of M&A and strategic advisory assignments, as well as numerous private and public financings, as both an advisor and principal.
Prior to joining England & Company in 2015, Mr. Cowherd was a Managing Director of Healthcare Investment Banking at Mesirow Financial. He also served as a Managing Director at Peter J. Solomon Company, Salomon Brothers, and BT Securities / Bankers Trust Co. In addition, Mr. Cowherd was a founding member and General Partner of Atlantic Medical Capital, LP, a private equity firm focused on the healthcare industry.
Mr. Cowherd earned his AB from Princeton University and his MBA from the Stanford University Graduate School of Business.
Bruce Craig has over 25 years of venture capital, M&A, operations management and technical experience in the energy, communications, and industrial technology industries.
Prior to joining England & Company, he was a General Partner at Ideal Partners Fund, an energy and communications technology venture capital fund. Prior to Ideal Partners, he was Vice President of E3 Ventures, a hybrid venture-investment and strategic advisory firm, and Director of Utility Regulation and Environmental Affairs at the Natural Gas Supply Association. Previously, Mr. Craig worked in corporate finance with Conoco Inc., as a Director in program development within the US Environmental Protection Agency’s energy efficiency and pollution prevention programs and led engineering and business development teams for American Meter Company/Ruhrgas AG.
Mr. Craig earned his BS in Industrial Engineering from Lehigh University and his MBA in Finance from the Wharton School at the University of Pennsylvania.
Tom Crews has over 30 years of experience as an investment banker, entrepreneur, and corporate executive of energy technology and healthcare technology companies. As an investment banker, he has completed a wide range of sell-side M&A transactions, and venture capital and private equity financings for growth-stage technology companies.
Prior to joining England & Company in 2021, Mr. Crews was Managing Director and head of the energy tech practice group at Bowen Advisors, a Boston-based technology investment bank. Previously, Mr. Crews was a Managing Director with Stratford Partners where he provided M&A, strategic advisory, and turnaround advisory services to growth-stage companies, and a Principal with Skipping Stone, a strategic consulting firm focused exclusively on the energy industry. Prior to entering investment banking, Mr. Crews served as CEO for two venture capital-backed energy management companies (Pentech Solutions and Envenergy) and a medical device manufacturer (SynergEyes). He is also co-founder of INC Research (now Syneos Health), a multi-billion-dollar, global biopharmaceutical services company.
Mr. Crews earned his BA from Capital University and his MBA and JD from the Ohio State University.
Ramzi Nassar is an investment banker with over 20 years of experience in M&A, financial restructuring and strategic advisory services, and private and public financings. He has extensive advisory experience with transactions in the Energy, Healthcare, Technology, and Consumer sectors.
Prior to joining England & Company in 2021, Mr. Nassar was Senior Managing Director and Head of Energy Services Investment Banking at B. Riley Securities. He also served as a Managing Director and Head of Energy Investment Banking for Oppenheimer & Co. His previous investment banking experiences include energy and M&A roles at Citibank, CIBC World Markets, and Morgan Stanley. In addition, he has eight years of experience as CEO of eLinear Solutions, an energy IT services company.
Mr. Nassar earned his BA from Rice University and his MBA from the Sloan School of Management at MIT.
Richard NeJame is a senior investment banking executive with over 25 years of experience advising leveraged and distressed corporate clients, as well as institutional and other investing clients. His background includes capital raising, M&A, exchange offers, and Chapter 11 reorganizations. During his career, Mr. NeJame has executed more than $100 billion in aggregated transaction value involving over 80 deals.
Mr. NeJame started his career at Alex. Brown & Sons, where he became an integral part of the team that established the restructuring group at Lazard Frères & Co. He later led restructuring groups at Gleacher & Company and Oppenheimer & Co. Most recently, Mr. NeJame was a Senior Managing Director at B. Riley / FocalPoint prior to joining England & Company.
Mr. NeJame earned his BSE in Electrical Engineering from Duke University and received his MBA in Finance from the Wharton School of Business at the University of Pennsylvania.
Patrick O’Shea has over 15 years of investment banking and venture capital experience. Over the course of his career, he has participated in more than $11.5 billion of financings for companies in the energy, financial services, and telecommunications and technology sectors.
Prior to joining England & Company, Mr. O’Shea was a senior member of Cora Capital Advisors’ Corporate Finance team, where he focused on advising energy technology companies. Previously, Mr. O’Shea was a Vice President in JPMorgan’s Investment Banking division working in New York and Tokyo. Before joining JPMorgan’s Investment Banking division, Mr. O’Shea worked for LabMorgan, JPMorgan’s proprietary venture capital division. Mr. O’Shea began his career as a member of Merrill Lynch’s Investment Banking unit where he advised technology and telecommunications companies.
Mr. O’Shea earned his BSFS from Georgetown University’s School of Foreign Service, where he majored in International Economics with a background in Finance and Trade.
Joel Strauch has over 25 years of experience in M&A, capital raising, and strategic advisory services. Mr. Strauch has extensive experience working with companies in a range of technology sectors with a focus on SaaS and cloud and infrastructure software.
Prior to joining England & Company, Mr. Strauch was a Managing Director at DC Advisory and Signal Hill Capital, and a Partner at Updata Advisors. Over the course of his time at these three firms, Mr. Strauch developed and established a leading practice advising privately held growth companies in the infrastructure software segment. Mr. Strauch also has capital markets and debt financing experience from previous investment banking roles at FAC Equities, H.C Wainwright, and Alex. Brown & Sons. He also served as a manager arranging project financings at Mission Energy.
Mr. Strauch earned his BS in Finance at Loyola University.
Kian Kiat Tan has over 25 years of experience in investment banking, strategic consulting, and corporate multinationals. Mr. Tan has been involved in various fundraising, mergers and acquisitions, capital markets (Equity and Debt), and corporate restructuring transactions. He has also advised many public and private companies and financial sponsors on strategic transactions. In addition, he has been part of the senior management team within a multinational corporation focused on mergers and acquisitions and business development opportunities.
Prior to joining England & Company, Mr. Tan was an Executive Director with a UK residential real estate development company where he led the fundraising effort targeting institutional and family office investors. Previously, Mr. Tan worked at Nippon Paint, the large Japanese paint and coatings company, where he was the Head of Mergers and Acquisitions. Prior to Nippon Paint, Mr. Tan was a Director and Head of Southeast Asia for Avista Houlihan Lokey based in Singapore. Mr. Tan has in-depth experience with broad international exposure in mergers and acquisitions, fundraising, and corporate development strategy. He has successfully completed transactions valued at over $8 billion globally. Mr. Tan began his career in the UK as a Chartered Accountant and worked across Asia in a professional services firm, investment bank, and multinational corporation, focusing on the Real Estate, Consumer, TMT, Financial Services, Pharmaceutical & Healthcare, and Industrial sectors.
Mr. Tan is a Fellow Member of the Association of Chartered Certified Accountants (UK) (FCCA) and holds a degree (BA Hons) in Accountancy from De Montfort University. He received an MBA from the Chicago Booth School of Business, and a Postgraduate Degree Masters level, PGDip in Global Business from Oxford University’s Saïd Business school.
Paul Teitelbaum has over 25 years of healthcare investment banking, corporate development, and management experience, with a particular focus on medical technology and life sciences. He has completed numerous M&A, financing, and strategic partnership transactions for private and public companies.
Prior to joining England & Company in 2015, Mr. Teitelbaum was Managing Director of the Healthcare Investment Banking Group at Mesirow Financial. He also served as a Managing Director of Healthcare Investment Banking at Landmark Ventures, and as a healthcare investment banker at Robertson Stephens and Burnham Securities. Previously, Mr. Teitelbaum held corporate development and disease management roles at Schering-Plough (now Merck & Co., Inc.) and Wyeth-Lederle (now Pfizer, Inc.).
Mr. Teitelbaum received his BA in Biology summa cum laude from the University of Pennsylvania and his MBA in Finance from the Wharton School of the University of Pennsylvania.
